Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical devices, glasses, lens, and vision aid products. It is also involved in leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy services, as well as provides medical and scientific prescription eyeglasses. Furt… Read more
Universal Vision Biotechnology Co Ltd (3218) - Total Assets
Latest total assets as of September 2025: NT$5.94 Billion TWD
Based on the latest financial reports, Universal Vision Biotechnology Co Ltd (3218) holds total assets worth NT$5.94 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Universal Vision Biotechnology Co Ltd - Total Assets Trend (2003–2024)
This chart illustrates how Universal Vision Biotechnology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Universal Vision Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Universal Vision Biotechnology Co Ltd's total assets of NT$5.94 Billion consist of 49.3% current assets and 50.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.8% |
| Accounts Receivable | NT$565.57 Million | 9.8% |
| Inventory | NT$289.73 Million | 5.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Universal Vision Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Universal Vision Biotechnology Co Ltd's current assets represent 49.3% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2024, down from 15.9% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
Universal Vision Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Universal Vision Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.79 Billion |
|
Meinian Onehealth Healthcare Holdings Co Ltd
SHE:002044
|
China | CN¥19.57 Billion |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
China | CN¥6.55 Billion |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM1.12 Billion |
|
Optimax Holdings Sdn Bhd
KLSE:0222
|
Malaysia | RM146.00 Million |
|
Cengild Medical Berhad
KLSE:0243
|
Malaysia | RM218.07 Million |
|
DC HEALTHCARE HOLDINGS BERHAD
KLSE:0283
|
Malaysia | RM99.33 Million |
|
Raffles Medical Group Ltd
F:02M1
|
Germany | €1.49 Billion |
Universal Vision Biotechnology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Universal Vision Biotechnology Co Ltd generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Universal Vision Biotechnology Co Ltd generates $ 18.48 in net profit.
Universal Vision Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 2.05 | 2.18 |
| Quick Ratio | 2.17 | 1.85 | 2.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.70 Billion | NT$ 1.51 Billion | NT$ 888.66 Million |
Universal Vision Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Universal Vision Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | NT$5.76 Billion |
| Market Capitalization | $216.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Universal Vision Biotechnology Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Universal Vision Biotechnology Co Ltd's assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Universal Vision Biotechnology Co Ltd (2003–2024)
The table below shows the annual total assets of Universal Vision Biotechnology Co Ltd from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.76 Billion | +12.32% |
| 2023-12-31 | NT$5.13 Billion | +13.87% |
| 2022-12-31 | NT$4.51 Billion | +20.17% |
| 2021-12-31 | NT$3.75 Billion | +18.32% |
| 2020-12-31 | NT$3.17 Billion | +19.72% |
| 2019-12-31 | NT$2.65 Billion | +26.25% |
| 2018-12-31 | NT$2.10 Billion | +4.62% |
| 2017-12-31 | NT$2.00 Billion | +15.01% |
| 2016-12-31 | NT$1.74 Billion | -7.79% |
| 2015-12-31 | NT$1.89 Billion | +4.84% |
| 2014-12-31 | NT$1.80 Billion | +32.03% |
| 2013-12-31 | NT$1.37 Billion | +8.65% |
| 2012-12-31 | NT$1.26 Billion | -9.17% |
| 2011-12-31 | NT$1.38 Billion | +36.86% |
| 2010-12-31 | NT$1.01 Billion | -9.58% |
| 2009-12-31 | NT$1.12 Billion | +2.57% |
| 2008-12-31 | NT$1.09 Billion | +54.70% |
| 2007-12-31 | NT$704.59 Million | +17.55% |
| 2006-12-31 | NT$599.41 Million | +56.23% |
| 2004-12-31 | NT$383.68 Million | +24.73% |
| 2003-12-31 | NT$307.60 Million | -- |